CC
IMVT icon

Corton Capital’s Immunovant IMVT Stock Holding History

Corton Capital’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-9,027
Closed -$292K – 618
2024
Q1 		$292K Buy
+9,027
New +$329K 0.11% 282
2023
Q4 		– Sell
-7,505
Closed -$288K – 615
2023
Q3 		$288K Buy
+7,505
New +$170K 0.15% 202
2022
Q2 		– Sell
-19,854
Closed -$109K – 420
2022
Q1 		$109K Sell
19,854
-15,769
-44% -$98.2K 0.05% 386
2021
Q4 		$304K Buy
+35,623
New +$294K 0.13% 160

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Corton Capital's IMVT Position: Q2 2024 in Review

Corton Capital sold out of Immunovant (IMVT) in Q2 2024, closing a stake of 9,027 shares — an estimated $292K sold.

Corton Capital first reported a position in IMVT in Q4 2021 and held it in 4 quarters. The position peaked at $304K in Q4 2021. 197 funds tracked by Wall St. Rank hold IMVT as of Q2 2024.

  • Corton Capital reported no remaining Immunovant position as of Q2 2024 after selling out during the quarter.
  • Corton Capital sold 9,027 Immunovant shares in Q2 2024, an estimated $292K.
  • Corton Capital first reported a position in Immunovant in Q4 2021 and held it in 4 quarters.
  • Corton Capital's Immunovant position peaked at $304K in Q4 2021.
  • 197 funds tracked by Wall St. Rank held Immunovant as of Q2 2024.

Based on Corton Capital's 13F filing for Q2 2024, filed 14 Aug 2024.